Stock Track | Tempus AI Soars 7.34% Intraday on Launch of AI-Powered Cancer Treatment Prediction Algorithm
Stock Track
Feb 18
Tempus AI's stock surged 7.34% during intraday trading on Wednesday.
The significant price movement followed the company's announcement of the launch of HRD-RNA, a pan-cancer artificial intelligence algorithm designed to identify homologous recombination deficiency (HRD). The tool aims to predict which solid tumor patients may respond to platinum-based chemotherapy or PARP inhibitors.
Tempus AI cited a real-world validation study in metastatic pancreatic cancer, which indicated that patients identified as HRD-RNA-positive and treated with first-line platinum regimens showed a reduced mortality risk compared to those on non-platinum therapies. The full supporting data for this study are expected to be published later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.